Top ▲
Target id: 2083
Nomenclature: mitogen-activated protein kinase kinase kinase 8
Abbreviated Name: Cot
Family: STE-unique family
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 467 | 10p11.23 | MAP3K8 | mitogen-activated protein kinase kinase kinase 8 | |
Mouse | - | 467 | 18 2.73 cM | Map3k8 | mitogen-activated protein kinase kinase kinase 8 | |
Rat | - | 467 | 17q12.1 | Map3k8 | mitogen-activated protein kinase kinase kinase 8 |
Previous and Unofficial Names |
Cancer Osaka thyroid oncogene | ESTF | proto-oncogene c-COT | serine/threonine kinase (Tpl-2) |
Database Links | |
Alphafold | P41279 (Hs), Q07174 (Mm), Q63562 (Rn) |
BRENDA | 2.7.11.25 |
ChEMBL Target | CHEMBL4899 (Hs) |
Ensembl Gene | ENSG00000107968 (Hs), ENSMUSG00000024235 (Mm), ENSRNOG00000016378 (Rn) |
Entrez Gene | 1326 (Hs), 26410 (Mm), 116596 (Rn) |
Human Protein Atlas | ENSG00000107968 (Hs) |
KEGG Enzyme | 2.7.11.25 |
KEGG Gene | hsa:1326 (Hs), mmu:26410 (Mm), rno:116596 (Rn) |
OMIM | 191195 (Hs) |
Pharos | P41279 (Hs) |
RefSeq Nucleotide | NM_001244134 (Hs), NM_007746 (Mm), NM_053847 (Rn) |
RefSeq Protein | NP_005195 (Hs), NP_031772 (Mm), NP_446299 (Rn) |
UniProtKB | P41279 (Hs), Q07174 (Mm), Q63562 (Rn) |
Wikipedia | MAP3K8 (Hs) |
Enzyme Reaction | ||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service. A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform. http://www.millipore.com/techpublications/tech1/pf3036 http://www.reactionbiology.com/webapps/main/pages/kinase.aspx Reference: ...1 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: nd/COT1(MAP3K8) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
Immunopharmacology Comments |
MAP3K8 (a.k.a. TPL2) is the primary regulator of ERK-mediated gene transcription downstream of multiple proinflammatory stimuli [3,6]. Its expression and activation are modulated by a range of inflammatory receptors, including TLRs, TNFR1, IL-1R1 and IL-1R2 [5], and it is able to amplify local inflammation by promoting the production of several proinflammatory cytokines (e.g. TNFα, IL-1β, IL-6 and IL-8) . Tpl2-deficient mice are protected from inflammatory and autoimmune diseases. Pharmacological inhibitors of MAP3K8 are therefore considered to offer potential to disrupt excessive inflammation and reduce the associated tissue damage in human chronic inflammatory and auto-iimmune diseases. Gilead Sciences have an orally bioavailable, selective MAP3K8 inhibitor in clinical development; GS-4875 (structure not disclosed) has been advanced to Phase 2 evaluation for ulcerative colitis (NCT04130919, primary completion date April 2021) [7]. |
Immuno Process Associations | ||
|
||
|
||
|
||
|
||
|
1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1039-45. [PMID:22037377]
2. Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S. (2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA, 104 (51): 20523-8. [PMID:18077363]
3. Gantke T, Sriskantharajah S, Ley SC. (2011) Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase. Cell Res, 21 (1): 131-45. [PMID:21135874]
4. Gavrin LK, Green N, Hu Y, Janz K, Kaila N, Li HQ, Tam SY, Thomason JR, Gopalsamy A, Ciszewski G et al.. (2005) Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships. Bioorg Med Chem Lett, 15 (23): 5288-92. [PMID:16165349]
5. Senger K, Pham VC, Varfolomeev E, Hackney JA, Corzo CA, Collier J, Lau VWC, Huang Z, Hamidzhadeh K, Caplazi P et al.. (2017) The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation. Sci Signal, 10 (475). [PMID:28420753]
6. Xu D, Matsumoto ML, McKenzie BS, Zarrin AA. (2018) TPL2 kinase action and control of inflammation. Pharmacol Res, 129: 188-193. [PMID:29183769]
7. Zarrin AA, Bao K, Lupardus P, Vucic D. (2021) Kinase inhibition in autoimmunity and inflammation. Nat Rev Drug Discov, 20 (1): 39-63. [PMID:33077936]
STE-unique family: mitogen-activated protein kinase kinase kinase 8. Last modified on 08/01/2021. Accessed on 11/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=2083.